Durvalumab + FLOT Yields Significantly Improved EFS in Gastric/GEJ Cancer in MATTERHORN Trial

First Look With ASCO Daily News presents Dr. Julie Gralow, ASCO’s chief medical officer, on the results of the MATTERHORN trial, which assessed the benefits of adding durvalumab to 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel chemotherapy (FLOT) in patients with resectable gastric/gastroesophageal junction cancer. This abstract will be presented as LBA5 during the Plenary Session at the 2025 ASCO Annual Meeting. Read the full abstract: https://meetings.asco.org/abstracts-presentations/245972 For more on ASCO25, visit https://dailynews.ascopubs.org/meetings/asco-annual-meeting _Data as of May 19, 2025_

Video Lainnya